DE69924615D1 - Thymosin beta 4 stimuliert wundheilung - Google Patents

Thymosin beta 4 stimuliert wundheilung

Info

Publication number
DE69924615D1
DE69924615D1 DE69924615T DE69924615T DE69924615D1 DE 69924615 D1 DE69924615 D1 DE 69924615D1 DE 69924615 T DE69924615 T DE 69924615T DE 69924615 T DE69924615 T DE 69924615T DE 69924615 D1 DE69924615 D1 DE 69924615D1
Authority
DE
Germany
Prior art keywords
wound healing
stimulated wound
thymosine beta
thymosine
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924615T
Other languages
English (en)
Other versions
DE69924615T2 (de
DE69924615T3 (de
Inventor
K Kleinman
Allan Goldstein
M Malinda
Gabriel Sosne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22246605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69924615(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69924615D1 publication Critical patent/DE69924615D1/de
Publication of DE69924615T2 publication Critical patent/DE69924615T2/de
Application granted granted Critical
Publication of DE69924615T3 publication Critical patent/DE69924615T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/18—Thymus derived hormone or factor; related peptides
DE69924615T 1998-07-30 1999-07-29 Thymosin beta 4 stimuliert wundheilung Expired - Lifetime DE69924615T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9469098P 1998-07-30 1998-07-30
US94690P 1998-07-30
PCT/US1999/017282 WO2000006190A1 (en) 1998-07-30 1999-07-29 THYMOSIN β4 PROMOTES WOUND REPAIR

Publications (3)

Publication Number Publication Date
DE69924615D1 true DE69924615D1 (de) 2005-05-12
DE69924615T2 DE69924615T2 (de) 2006-02-02
DE69924615T3 DE69924615T3 (de) 2011-05-05

Family

ID=22246605

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924615T Expired - Lifetime DE69924615T3 (de) 1998-07-30 1999-07-29 Thymosin beta 4 stimuliert wundheilung

Country Status (12)

Country Link
US (6) US20070111931A9 (de)
EP (3) EP2311485A1 (de)
AT (1) ATE292473T1 (de)
AU (1) AU766826B2 (de)
CA (1) CA2338928A1 (de)
DE (1) DE69924615T3 (de)
DK (1) DK1100529T4 (de)
ES (1) ES2239846T5 (de)
HK (1) HK1038307A1 (de)
MX (1) MXPA01001041A (de)
PT (1) PT1100529E (de)
WO (1) WO2000006190A1 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040131626A1 (en) * 2001-03-15 2004-07-08 Goldstein Allan L. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (tb4) analogues, isoforms and other derivatives
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
US20070191275A1 (en) * 1998-07-30 2007-08-16 Regenerx Biopharmaceuticals, Inc. Method of treating, preventing, inhibiting or reducing damage to cardiac tissue with thymosin beta 4 fragments
US20040170625A1 (en) * 1998-07-30 2004-09-02 Regenerx Biopharmaceuticals, Inc. Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivatives
EP2311485A1 (de) 1998-07-30 2011-04-20 The Government of the United States of America, as represented by the Secretary of Health and Human Services Thymosin beta 4 stimuliert Wundheilung
US20070015698A1 (en) * 1998-07-30 2007-01-18 United States Of America As Represented By The Secretary Of Health Treatment of skin, and wound repair, with thymosin beta 4
US6855806B1 (en) 1999-10-15 2005-02-15 Curagen Corporation Thymosin beta 10-like proteins and nucleic acids encoding same
US6992170B2 (en) 1999-10-15 2006-01-31 Curagen Corporation Polypeptides and polynucleotides homologous to thymosin, ephrin a receptors, and fibromodulin
DE10030149A1 (de) * 2000-06-20 2002-01-10 Switch Biotech Ag Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen oder Wundheilung sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
FR2814076B1 (fr) * 2000-09-21 2002-12-20 Centre Nat Rech Scient Agent angiogenique et ses utilisations
AU1351302A (en) * 2000-11-02 2002-05-15 Regenerx Biopharmaceuticals Inhibition or reversal of skin aging by actin-sequestering peptides
US20110217394A1 (en) * 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
US8574642B2 (en) 2000-12-05 2013-11-05 Tahitian Noni International, Inc. Antiviral Morinda citrifolia L. based formulations and methods of administration
US8790727B2 (en) * 2000-12-05 2014-07-29 Tahitian Noni International, Inc. Morinda citrifolia and iridoid based formulations
US8652546B2 (en) 2007-09-06 2014-02-18 Tahitian Noni International, Inc. Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals
US20040192761A1 (en) * 2003-03-25 2004-09-30 Palu Afa Kehaati Preventative and treatment effects of morinda citrifolia as an aromatase inhibitor
US20110171333A1 (en) * 2000-12-05 2011-07-14 Bryant Wadsworth Morinda Citrifolia Based Antioxidant and Antimicrobial Formulations for Improved Color Stability and Increased Shelf Life of Various Meat Products
US6855345B2 (en) * 2001-11-02 2005-02-15 Morinda, Inc. Preventative and treatment effects of Morinda citrifolia on diabetes and its related conditions
US20070196527A1 (en) * 2006-02-23 2007-08-23 Jensen Claude J Preventative and treatment effects of Morinda citrifolia on Osteoarthritis and its related conditions
US7244463B2 (en) * 2005-10-18 2007-07-17 Tahitian Noni International, Inc. Garcinia mangostana L. enhanced animal food product
AU2006233251B2 (en) * 2001-03-15 2008-10-02 Regenerx Biopharmaceuticals, Inc. Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives
US7018662B2 (en) * 2001-04-17 2006-03-28 Morinda, Inc. Palliative effects of morinda citrifolia oil and juice
AU2002309842B2 (en) * 2001-05-17 2006-02-02 Regenerx Biopharmaceuticals, Inc. Treating epidermlyosis bullosa with thymosin beta 4
WO2003020215A2 (en) 2001-08-29 2003-03-13 Regenerx Biopharmaceuticals, Inc. Methods of treating mycocardial event related coditions with thymosin beta 4
US7070813B2 (en) * 2001-11-02 2006-07-04 Morinda, Inc. Preventative and treatment effects of morinda citrifolia as a colon cancer cell growth inhibitor
US7442395B2 (en) * 2002-11-14 2008-10-28 Tahitian Noni International, Inc. Formulation for treating candidiasis using Morinda citrifolia
US20110160057A1 (en) * 2001-11-14 2011-06-30 Bryant Wadsworth Morinda Citrifolia Based Antimicrobial Formulations
GB0130608D0 (en) 2001-12-21 2002-02-06 Psimedica Ltd Medical fibres and fabrics
TWI353849B (en) * 2002-01-25 2011-12-11 Us Gov Health & Human Serv Methods and compositions for the promotion of hair
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
CA2475053A1 (en) * 2002-02-06 2004-04-29 Regenerx Biopharmaceuticals, Inc. Treatment of microbial infections and associated gastrointestinal disorders with thymosin .beta.4
AU2008201749B2 (en) * 2002-02-06 2010-05-13 Regenerx Biopharmaceuticals, Inc. Treatment of Infections and Other Disorders
CA2481958A1 (en) * 2002-04-12 2003-10-23 Yale University Anti-inflammatory and wound healing effects of lymphoid thymosin .beta.-4
US6821524B2 (en) * 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
JP2007525445A (ja) * 2003-03-31 2007-09-06 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ４、類似体、アイソフォーム及び他の誘導体を送達するための組成物及び方法
US20060269630A1 (en) * 2003-04-16 2006-11-30 Palu Afa K Morinda citrifolia as a 5-Lipoxygenase inhibitor
JP4073826B2 (ja) * 2003-06-04 2008-04-09 タヒチアン ノニ インターナショナル インコーポレーテッド ヤエヤマアオキの抽出物を含む農業用活力剤
US20060246057A1 (en) * 2003-07-18 2006-11-02 Regenerx Biopharmaceuticals, Inc Treatment or prevention of damage due to radiation exposure
US20070259060A1 (en) * 2003-08-12 2007-11-08 Mian-Ying Wang Formulations and Methods for Treating Breast Cancer with Morinda Citrifolia and Methylsulfonymethane
EP1706136A4 (de) * 2003-12-22 2009-09-16 Regenerx Biopharmaceuticals Verfahren zur behandlung oder verhinderung von biologischen oder immunantworten auf einen reaktiven chemischen oder biologischen oder toxischen stoff
CN1926151A (zh) 2004-03-05 2007-03-07 雷金纳克斯生物制药公司 治疗或预防细胞外基质积聚
WO2006023879A1 (en) 2004-08-20 2006-03-02 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
KR20070083487A (ko) * 2004-08-20 2007-08-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 심장 조직의 손상을 치료, 예방, 억제 또는 감소시키는방법
AU2006204785B2 (en) * 2005-01-13 2010-11-25 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
US20060204601A1 (en) * 2005-03-09 2006-09-14 Palu Afa K Formulations and methods for preventing and treating substance abuse and addiction
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
US20060280818A1 (en) * 2005-05-26 2006-12-14 Palu Afa K Nicotinic acetylcholine receptor antagonist
JP2008543879A (ja) * 2005-06-17 2008-12-04 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔペプチド組成物ならびに方法
EP1908779B1 (de) * 2005-07-15 2013-01-09 Beijing Northland Biotech Co. Ltd. Thymosin-beta-4-derivate und verwendung davon
KR20080032221A (ko) * 2005-07-26 2008-04-14 리지너크스 바이오 파마소티컬스, 인코포레이티드 울혈성 심부전으로 인한 조직 악화, 부상 또는 손상을 치료또는 예방하는 방법
US20070184137A1 (en) * 2005-11-29 2007-08-09 Palu Afa K Morinda Citrifolia L. Based Formulations for Inhibiting Matrix Metalloproteinase Enzymes
US20070154579A1 (en) * 2005-11-29 2007-07-05 Palu Afa K Morinda Citrifolia Based Formulation And Methods For Weight Management
US20070166417A1 (en) * 2005-11-29 2007-07-19 Palu Afa K Formulation and Methods for Use of Morinda Citrifolia Seed Oil
EP1960009B1 (de) 2005-12-13 2011-11-23 The President and Fellows of Harvard College Gerüste zur zelltransplantation
ES2600806T3 (es) * 2006-01-17 2017-02-10 Regenerx Biopharmaceuticals, Inc. Procedimientos para tratar o prevenir el daño tisular causado por aumento de flujo sanguíneo
US20070281903A1 (en) * 2006-05-04 2007-12-06 Palu Afa K Morinda Citrifolia-Based Formulation 5-LOX And 15-LOX
US8535741B2 (en) 2006-05-12 2013-09-17 Morinda, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8025910B2 (en) 2006-05-12 2011-09-27 Tahitian Noni International, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
JP2010501486A (ja) * 2006-08-18 2010-01-21 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 移植用の臓器又は組織を保存及び／又は調製するための方法及び組成物
US8399412B2 (en) * 2006-10-06 2013-03-19 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions
EP2091557A2 (de) 2006-11-15 2009-08-26 Coda Therapeutics, INC. Verbesserte verfahren und zusammensetzungen zur wundheilung
CA2621452A1 (en) * 2007-02-21 2008-08-21 Innovational Holdings, Llc Stent and method for reducing tissue damage after ischemic injury with thymosin b4
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US20080317890A1 (en) * 2007-06-21 2008-12-25 Claude Jarakae Jensen Method for treating visual impairment through the prophylactic administration of a morinda citrifolia-based naturaceutical
WO2009033816A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
WO2009043464A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Astressin and beta- endorphin for use as therapeutic agents
US20100210540A1 (en) * 2007-09-11 2010-08-19 Dorian Bevec Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
US9035037B2 (en) 2007-12-21 2015-05-19 Coda Therapeutics, Inc. Medical devices
US20090196944A1 (en) * 2008-02-01 2009-08-06 Brad Rawson Methods of Manufacture of Morinda Citrifolia Based Compositions for Treatment of Anti-Inflammatory Diseases through Inhibition of Cox-1, Cox-2, Interleukin -1beta, Interleukin-6, TNF-alpha, HLE, and iNOS
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
HUE058891T2 (hu) 2008-08-26 2022-09-28 Hope City Módszer és készítmények a T-sejtek fokozott tumorellenes effektor mûködésének fokozására
AU2010229770B2 (en) * 2009-03-26 2016-10-06 Henry Ford Health System Methods for improving neurological outcome after neural injury and neurodegenerative disease
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
US8230654B2 (en) 2009-06-10 2012-07-31 Comc, Llc Medallion insert for modular flooring assemblies
US8782989B2 (en) 2009-06-11 2014-07-22 Comc, Llc Narrow lined modular flooring assemblies
AU2010278702C1 (en) 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
GB2476789A (en) 2009-11-10 2011-07-13 Gl Holdings Inc Bv Use of thymosin for treatment of type 2 diabetes
US20110206786A1 (en) * 2010-02-23 2011-08-25 Brett Justin West Acai and Iridoid Based Formulations
EP2542230A4 (de) * 2010-03-05 2013-08-28 Harvard College Förderung des anwachsens von skelettmuskel-stammzellen durch gleichzeitige verabreichung von vegf und igf-1
KR101297037B1 (ko) * 2010-03-26 2013-08-14 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
EP2585053A4 (de) 2010-06-25 2014-02-26 Harvard College Gemeinsame freisetzung von stimulations- und hemmfaktoren zur erzeugung von temporär stabilen und räumlich begrenzten zonen
WO2012044783A2 (en) * 2010-09-30 2012-04-05 Regenerx Biopharmaceuticals, Inc. Method of achieving a thymosin beta 4 concentration in a human patient
KR102155383B1 (ko) 2010-10-06 2020-09-11 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 재료에 기초한 세포 치료를 위한 주사 가능한 기공 형성 하이드로겔
US9603894B2 (en) 2010-11-08 2017-03-28 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
WO2012148684A1 (en) 2011-04-27 2012-11-01 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
WO2012149358A1 (en) 2011-04-28 2012-11-01 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
AU2012261848B2 (en) 2011-06-03 2017-06-15 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US20130022687A1 (en) 2011-07-19 2013-01-24 Fitzgerald Jr John James Topical transdermal method for delivering nutrients through the skin for expedited wound healing
US8632827B2 (en) * 2011-12-13 2014-01-21 Avon Products, Inc Modulation of thymosin beta-4 in skin
US9775883B2 (en) 2011-12-23 2017-10-03 Henry Ford Health System Methods, systems, and compositions for promoting recovery of peripheral neuropathy
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9808654B2 (en) 2013-02-11 2017-11-07 Jan Marini Skin Research Post procedure skin care gel and methods of use thereof
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
DE102013017203A1 (de) * 2013-10-16 2015-04-16 Isa Atay Thymustherapie
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
CN114010788A (zh) 2014-08-22 2022-02-08 奥克兰联合服务有限公司 通道调节剂
KR101530278B1 (ko) * 2014-09-04 2015-06-24 부산대학교 산학협력단 심근전환유전자 및 심혈관재생유전자를 포함하는 아데노부속바이러스를 유효성분으로 포함하는, 허혈성 심장질환 예방 또는 치료용 조성물
AU2015317351B2 (en) 2014-09-19 2020-07-02 City Of Hope Costimulatory chimeric antigen receptor T cells targeting IL3Ra2
JP6634451B2 (ja) * 2014-10-22 2020-01-22 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４を含有する組成物、およびそれを含む医薬製剤
WO2016112049A1 (en) 2015-01-06 2016-07-14 Cardiovascular Biotherapeutics, Inc. Angiogenic treatment of ischemic heart disease
WO2016112051A1 (en) * 2015-01-06 2016-07-14 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for wound healing
EP3250250A4 (de) 2015-01-30 2019-05-22 President and Fellows of Harvard College Peritumorale und intratumorale materialien zur krebstherapie
CA2976675A1 (en) 2015-02-16 2016-08-25 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treating erectile conditions
US11150242B2 (en) 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
US10781595B2 (en) 2015-09-10 2020-09-22 Comc, Llc Modular flooring assemblies
US10744088B2 (en) 2015-10-06 2020-08-18 G-Treebnt Co., Ltd. Method for preparing ophthalmic preparation containing thymosin beta-4
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
EP4043010A1 (de) * 2016-05-06 2022-08-17 Phasebio Pharmaceuticals, Inc. Elp-fusionsproteine zur gesteuerten und verzögerten freisetzung
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
KR102340750B1 (ko) 2017-03-03 2021-12-21 에이치엘비테라퓨틱스 주식회사 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제
CN110585055B (zh) * 2019-08-26 2023-06-13 武汉贝缇安卡医疗健康投资有限公司 AcSDKP在增加成纤维细胞分泌Ⅲ型胶原蛋白含量的应用
CN111249534B (zh) * 2020-01-16 2021-06-15 中国人民解放军总医院 可用于促进创面组织同步修复再生的生物活性支架及其制备方法
AU2021251785A1 (en) * 2020-04-07 2022-11-03 Combangio, Inc. Lyophilized mesenchymal stem cell derived secretome and uses thereof
CN111888462B (zh) * 2020-08-10 2022-08-26 中国人民解放军军事科学院军事医学研究院 胸腺素β4在制备微生态平衡调节剂中的应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261982A (en) * 1977-11-09 1981-04-14 The Procter & Gamble Company Therapeutic composition
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4389343A (en) * 1981-12-24 1983-06-21 Hoffmann-La Roche Inc. Immunopotentiating peptides from thymus
US4388234A (en) * 1981-12-28 1983-06-14 Hoffmann-La Roche Inc. Peptide isolation
FR2530466A1 (fr) 1982-07-21 1984-01-27 Hecmati Michel Gel anti-ride, produit et procede
JPS61500431A (ja) 1982-12-09 1986-03-13 ビルトン，ジエラルド　エル． 傷治癒に有用な活性化され、安定化された酵素
BR8307692A (pt) 1983-03-01 1985-02-20 Rudolf Trensch Composicao de tratamento de cabelo e processo para o tratamento de cabelo
US4543340A (en) * 1983-04-07 1985-09-24 George Washington University Radioimmunoassay of thymosin β4
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
JPS60142908A (ja) 1983-12-29 1985-07-29 Kanebo Ltd 養毛化粧料
GB8517402D0 (en) * 1985-07-10 1985-08-14 Wellcome Found Treatment of viral infections
US4713394A (en) 1986-01-17 1987-12-15 Thornfeldt Carl R Treatment of nonacne inflammatory and infectious dermatoses and hair loss
JPS62252711A (ja) 1986-04-24 1987-11-04 Hideharu Tamaki 養毛剤
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
JPH02101019A (ja) * 1988-10-05 1990-04-12 Genichiro Soma 抗エイズ剤
JPH02142717A (ja) 1988-11-22 1990-05-31 Kanebo Ltd 養毛化粧料
US5654267A (en) * 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
EP0410348A1 (de) 1989-07-26 1991-01-30 G.D. Searle & Co. Topische Spironolakton-Zusammensetzung
US5068315A (en) 1990-04-12 1991-11-26 University Of Dundee Composition for the regulation of hair growth
GB9014221D0 (en) 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
JPH04234325A (ja) * 1990-12-27 1992-08-24 Hoechst Japan Ltd 脳および神経障害治療予防剤
CN1701814A (zh) * 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
WO1994018988A2 (en) * 1993-02-22 1994-09-01 Von Arnim Ulrich Christoph Use of heparins for the treatment of inflammatory or immunological diseases
AU6771594A (en) * 1993-04-22 1994-11-08 George Washington University, The Method of decreasing the toxicity of therapeutic compositions using thymosin beta 4
US5358703A (en) * 1993-09-27 1994-10-25 Mcw Research Foundation, Inc. Method for the detection of nitric oxide
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
EP0725652A1 (de) * 1993-10-07 1996-08-14 The George Washington University Medical Center Verfahren zur behandlung von septischen schocks mit thymisin b4
FR2711060B1 (fr) * 1993-10-13 1995-11-17 Oreal Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet.
US5591716A (en) * 1993-11-19 1997-01-07 New York University Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
US5652209A (en) * 1994-04-29 1997-07-29 University Of Miami Use of secretory products of human lacrimal gland acinar epithelia for tear replacement therapy
FR2719481B1 (fr) 1994-05-05 1996-05-31 Oreal Composition à base de composés antifongiques et de composés antibactériens halogènes pour diminuer la chute des cheveux.
JPH07316022A (ja) 1994-05-24 1995-12-05 Kyowa Hakko Kogyo Co Ltd 育毛剤
JP3202135B2 (ja) 1994-08-10 2001-08-27 カネボウ株式会社 頭髪化粧料
DE19509354A1 (de) * 1994-12-08 1996-06-13 Klett Loch Lore M Kombinationspräparat zur Förderung des Haarwachstums und ggf. des Haut- und Nagelwachstums sowie zur Verhinderung bzw. zur Beseitigung von Haarausfall
FR2741076B1 (fr) * 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques derives des hormones thymiques, leur utilisation a titre de medicament et compositions les contenant
DE19622422A1 (de) * 1996-06-04 1997-12-11 Sanorell Pharma Gmbh & Co Lagerungsstabile pharmazeutische Zusammensetzung mit immun - modulierenden und antiinflammatorischen Eigenschaften sowie ein Verfahren zu dessen Herstellung
US5663071A (en) * 1996-06-17 1997-09-02 Children's Medical Center Corporation Human thymosin β 15 gene, protein and uses thereof
JP3128203B2 (ja) * 1997-02-10 2001-01-29 一男 坪田 分泌腺細胞とリンパ球との接着阻害剤
DE19711939A1 (de) * 1997-03-21 1998-09-24 Bosch Gmbh Robert Vorrichtung zur Erfassung des Drucks und der Temperatur im Saugrohr einer Brennkraftmaschine
DE19731420A1 (de) * 1997-07-22 1999-01-28 Bosch Gmbh Robert Vorrichtung zur Erfassung des Drucks und der Temperatur im Saugrohr einer Brennkraftmaschine und Verfahren zu ihrer Herstellung
US6030948A (en) * 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
US20040067227A1 (en) * 2001-11-02 2004-04-08 Goldstein Allan L. Inhibition or reversal of skin aging by actin-sequestering peptides
EP2311485A1 (de) * 1998-07-30 2011-04-20 The Government of the United States of America, as represented by the Secretary of Health and Human Services Thymosin beta 4 stimuliert Wundheilung
US6586403B1 (en) * 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
AU1351302A (en) 2000-11-02 2002-05-15 Regenerx Biopharmaceuticals Inhibition or reversal of skin aging by actin-sequestering peptides
US7560280B2 (en) * 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
US6821524B2 (en) * 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
JP3870918B2 (ja) * 2002-10-23 2007-01-24 株式会社デンソー 温度センサ一体型圧力センサ装置
RU2295963C1 (ru) 2005-10-18 2007-03-27 Закрытое акционерное общество Научно-производственное предприятие "Тринита" Способ получения иммуностимулятора

Also Published As

Publication number Publication date
DE69924615T2 (de) 2006-02-02
AU5244399A (en) 2000-02-21
CA2338928A1 (en) 2000-02-10
MXPA01001041A (es) 2002-06-04
EP1100529B1 (de) 2005-04-06
DK1100529T3 (da) 2005-12-19
ATE292473T1 (de) 2005-04-15
PT1100529E (pt) 2005-10-31
EP1591128A1 (de) 2005-11-02
US20070111931A9 (en) 2007-05-17
EP1100529A1 (de) 2001-05-23
WO2000006190A1 (en) 2000-02-10
US20170326207A1 (en) 2017-11-16
ES2239846T3 (es) 2005-10-01
EP1100529B2 (de) 2010-08-25
US8143218B2 (en) 2012-03-27
US20110124550A1 (en) 2011-05-26
EP2311485A1 (de) 2011-04-20
ES2239846T5 (es) 2011-03-04
DE69924615T3 (de) 2011-05-05
DK1100529T4 (da) 2010-12-20
US20040220111A1 (en) 2004-11-04
US20090023663A1 (en) 2009-01-22
HK1038307A1 (en) 2002-03-15
AU766826B2 (en) 2003-10-23
US7268118B2 (en) 2007-09-11
US20070009469A1 (en) 2007-01-11
US20030060405A1 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
DE69924615D1 (de) Thymosin beta 4 stimuliert wundheilung
DE69839529D1 (de) Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
ATE84420T1 (de) Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
DE69827001D1 (de) Gewebedezellularization
DE69728057D1 (de) Iontophoretische auslösbare lieferungsvorrichtung zur verminderung von elektrischen empfindungen
NO963742L (no) Fremgangsmåte til å stimulere hematopoese med hemaglobin
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
DE3781263T2 (de) Peptid-derivate und deren verwendung in der therapie.
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
DE3578611D1 (de) Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
NO920125D0 (no) Fremgangsmaate for aa bestemme den funksjonelle aktivitetentil fri protein s eller protein c i en plasma-proeve
ATE239225T1 (de) Injektion durch elektromigration von einer mikroreservoir elektrode in ein kapillares separationssystem
DK403384D0 (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
DK0471030T3 (da) Glycoproteinhormonreceptormolekyler
NO873437L (no) Human placenta angiogen faktor i stand til aa stimulere kapillaer endotelcelle-proteasesyntese, dna-syntese og migrasjon.
SE9803962L (sv) Nukleinsyra som kodar för natriumtunnel i nervvävnad
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
DE295827T1 (de) Verwendung von 24,25-dihydroxycholecalciferol bei der heilung von knochenbruechen.
IT1286183B1 (it) Uso della relaxina come agente farmacologico per la produzione di farmaci per la cura delle gestosi gravidiche
IT1286182B1 (it) Impiego della relaxina o relassina, come nuovo agente farmacologico antistaminico per bloccare il rilascio di istamina nei tessuti in
MX9710291A (es) Inhibidores ligantes de proteinas de fijacion con factor de crecimiento del tipo de insulina y metodos de uso para los mismos.
ATE79636T1 (de) Peptid-derivate und deren verwendung in der therapie.

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: KLUNKER, SCHMITT-NILSON, HIRSCH, 80797 MUENCHEN

8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings